Clinical trialPhase 1 / Phase 2Recruiting
NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer
A Phase I/II Clinical Trial of NALIRIFOX Combined With Adebrelimab and PULSAR as First-Line Treatment for Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma
- Outcome
- Ongoing
- Phase
- Phase 1 / Phase 2
- Status
- Recruiting
- Study type
- Interventional
- Start
- April 2026
- Expected end
- March 2029
- Enrollment
- 55 participants
- Sites
- 1
- Primary outcomes
- Objective response rate (RECIST v1.1)
- Sponsor
- Other
- Results posted
- No
- Last update
- 19 May 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 18
- BackgroundTumor immune microenvironment in pancreatic ductal adenocarcinoma revisited - Exploring the "Space". DOI 10.1016/j.canlet.2025.217699↗
- BackgroundUnderstanding the PULSAR effect in combined radiotherapy and immunotherapy using transformer-based attention mechanisms. DOI 10.3389/fonc.2024.1497351↗
- BackgroundPULSAR Effect: Revealing potential synergies in combined radiation therapy and immunotherapy via differential equations. DOI 10.1016/j.jtbi.2024.111974↗
- BackgroundRadiotherapy, immunity, and immune checkpoint inhibitors. DOI 10.1016/s1470-2045(24)00075-5↗
- BackgroundPanoramic tumor microenvironment in pancreatic ductal adenocarcinoma. DOI 10.1007/s13402-024-00970-6↗
- BackgroundAn AI-based approach for modeling the synergy between radiotherapy and immunotherapy. DOI 10.1038/s41598-024-58684-6↗
- BackgroundGlobal cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. DOI 10.3322/caac.21834↗
- BackgroundImmune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a… DOI 10.1016/j.radonc.2023.109941↗
- BackgroundNALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarc… DOI 10.1016/s0140-6736(23)01366-1↗
- BackgroundRadio-immune response modelling for spatially fractionated radiotherapy. DOI 10.1088/1361-6560/ace819↗
- BackgroundEmerging evidence for adapting radiotherapy to immunotherapy. DOI 10.1038/s41571-023-00782-x↗
- BackgroundThe importance of hypoxia in radiotherapy for the immune response, metastatic potential and FLASH-RT. DOI 10.1080/09553002.2021.1988178↗
- BackgroundChallenges and Future Perspectives of Immunotherapy in Pancreatic Cancer. DOI 10.3390/cancers13164235↗
- BackgroundPersonalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR) in Preclinical Models Enhances Single-Agent … DOI 10.1016/j.ijrobp.2021.03.047↗
- BackgroundIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. DOI 10.1056/nejmoa1304369↗
- BackgroundSafety and activity of anti-PD-L1 antibody in patients with advanced cancer. DOI 10.1056/nejmoa1200694↗
- BackgroundFOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. DOI 10.1056/nejmoa1011923↗
- BackgroundPhase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. DOI 10.1097/cji.0b013e3181eec14c↗